Search research articles
Contact Us
Filters
Showing results (141-150 of 195) with videos related to
Page
of 20
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
May 11, 2010
The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all
Gil Y Melmed, Brennan M Spiegel, Brian Bressler, et al.
Journal of Crohn'S & Colitis
|
June 13, 2021
A Crohn's Disease-associated IL2RA Enhancer Variant Determines the Balance of T Cell Immunity by Regulating Responsiveness to IL-2 Signalling
Rimma Goldberg, Jennie N Clough, Luke B Roberts, et al.
Inflammatory Bowel Diseases
|
April 9, 2016
Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness Panel
Shane M Devlin, Gil Y Melmed, Peter M Irving, et al.
Contemporary Clinical Trials Communications
|
December 17, 2025
Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease
Silvio Danese, Bruce E Sands, Brian G Feagan, et al.
The Lancet. Gastroenterology & Hepatology
|
April 19, 2024
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study
Neil Chanchlani, Simeng Lin, Claire Bewshea, et al.
Frontline Gastroenterology
|
July 27, 2018
Golimumab: early experience and medium-term outcomes from two UK tertiary IBD centres
Mark A Samaan, Polychronis Pavlidis, Jonathan Digby-Bell, et al.
Journal of Crohn'S & Colitis
|
October 5, 2023
Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial
Marc Ferrante, Peter M Irving, Maria T Abreu, et al.
Drugs
|
June 4, 2020
Correction to: The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
HoUng Kim, Rieke Alten, Luisa Avedano, et al.
Gastrohep
|
December 28, 2020
The effects of COVID-19 on IBD prescribing and service provision in a UK tertiary centre
Esha Sharma, Susanna Meade, Francesca D'Errico, et al.
Drugs
|
February 1, 2020
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
HoUng Kim, Rieke Alten, Luisa Avedano, et al.
Page
of 20
Search research articles
Search
Showing results (141-150 of 195) with videos related to
Sort By:
Page
of 20
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
May 11, 2010
The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all
Gil Y Melmed, Brennan M Spiegel, Brian Bressler, et al.
Journal of Crohn'S & Colitis
|
June 13, 2021
A Crohn's Disease-associated IL2RA Enhancer Variant Determines the Balance of T Cell Immunity by Regulating Responsiveness to IL-2 Signalling
Rimma Goldberg, Jennie N Clough, Luke B Roberts, et al.
Inflammatory Bowel Diseases
|
April 9, 2016
Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness Panel
Shane M Devlin, Gil Y Melmed, Peter M Irving, et al.
Contemporary Clinical Trials Communications
|
December 17, 2025
Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease
Silvio Danese, Bruce E Sands, Brian G Feagan, et al.
The Lancet. Gastroenterology & Hepatology
|
April 19, 2024
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study
Neil Chanchlani, Simeng Lin, Claire Bewshea, et al.
Frontline Gastroenterology
|
July 27, 2018
Golimumab: early experience and medium-term outcomes from two UK tertiary IBD centres
Mark A Samaan, Polychronis Pavlidis, Jonathan Digby-Bell, et al.
Journal of Crohn'S & Colitis
|
October 5, 2023
Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial
Marc Ferrante, Peter M Irving, Maria T Abreu, et al.
Drugs
|
June 4, 2020
Correction to: The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
HoUng Kim, Rieke Alten, Luisa Avedano, et al.
Gastrohep
|
December 28, 2020
The effects of COVID-19 on IBD prescribing and service provision in a UK tertiary centre
Esha Sharma, Susanna Meade, Francesca D'Errico, et al.
Drugs
|
February 1, 2020
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
HoUng Kim, Rieke Alten, Luisa Avedano, et al.
Page
of 20